Related Experiment Video
Updated: Feb 12, 2026

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
Published on: August 14, 2018
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
Elisabeth F P Peterse1, Bertine Niessen1, Ruben D Addie1
1Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Introduction:
Chondrosarcoma is a malignant cartilage-forming bone tumour in which mutations in IDH1 and IDH2 frequently occur. Previous studies suggest an increased dependency on glutaminolysis in IDH1/2 mutant cells, which resulted in clinical trials with the drugs CB-839, metformin and chloroquine. In this study, the preclinical rationale for using these drugs as a treatment for chondrosarcoma was evaluated.
Methods:
Expression of glutaminase was determined in 120 cartilage tumours by immunohistochemistry. Ten chondrosarcoma cell lines were treated with the metabolic compounds CB-849, metformin, phenformin (lipophilic analogue of metformin) and chloroquine.
Results:
A difference in glutaminase expression levels between the different tumour grades (p = 0.001, one-way ANOVA) was identified, with the highest expression observed in high-grade chondrosarcomas. Treatment with CB-839, metformin, phenformin or chloroquine revealed that chondrosarcoma cell lines are sensitive to glutaminolysis inhibition. Metformin and phenformin decreased mTOR activity in chondrosarcoma cells, and metformin decreased LC3B-II levels, which is counteracted by chloroquine.
Conclusion:
Targeting glutaminolysis with CB-839, metformin, phenformin or chloroquine is a potential therapeutic strategy for a subset of high-grade chondrosarcomas, irrespective of the presence or absence of an IDH1/2 mutation.
Insights
Targeting glutaminolysis with drugs like CB-839 and metformin shows promise for treating high-grade chondrosarcoma. These metabolic inhibitors are effective against chondrosarcoma cell lines, offering a potential new therapeutic strategy.
Area of Science:
- Oncology
- Metabolic Pathways
- Cancer Therapeutics
Background:
- Chondrosarcoma, a malignant cartilage tumor, often harbors IDH1/2 mutations.
- IDH1/2 mutant cells show increased reliance on glutaminolysis.
- Existing clinical trials explore glutaminolysis inhibitors (CB-839, metformin, chloroquine) for chondrosarcoma.
Purpose of the Study:
- Evaluate the preclinical rationale for using glutaminolysis inhibitors in chondrosarcoma treatment.
- Assess the efficacy of CB-839, metformin, phenformin, and chloroquine against chondrosarcoma.
- Investigate the impact of these drugs on cellular metabolism and signaling pathways.
Main Methods:
- Immunohistochemistry used to determine glutaminase expression in 120 cartilage tumors.
- Ten chondrosarcoma cell lines treated with CB-839, metformin, phenformin, and chloroquine.
- Analysis of mTOR activity and LC3B-II levels in response to treatment.
Main Results:
- Glutaminase expression varied significantly with tumor grade, highest in high-grade chondrosarcomas.
- Chondrosarcoma cell lines demonstrated sensitivity to glutaminolysis inhibition.
- Metformin and phenformin reduced mTOR activity; metformin decreased LC3B-II levels, which chloroquine counteracted.
Conclusions:
- Inhibiting glutaminolysis via CB-839, metformin, phenformin, or chloroquine presents a viable therapeutic strategy.
- This approach is potentially effective for a subset of high-grade chondrosarcomas.
- Treatment efficacy is independent of IDH1/2 mutation status.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
Self Within Cultural Contexts
Impact of Social Context on Individuals
Mutation, Gene Flow, and Genetic Drift

